{"title":"Potential Drug-Drug Interactions and their Associated Factors at the University Children's Hospital in Syria: A Cross-Sectional Study","authors":"Linda Hsien, Samir Srour","doi":"10.35516/jjps.v17i1.1606","DOIUrl":null,"url":null,"abstract":"Objective: Polypharmacy among pediatric inpatients is common and exposes children to the risk of drug-drug interactions (DDIs). This study aimed to characterize potential DDIs (pDDIs) and their associated risk factors among pediatric inpatients.\nMethods: A cross-sectional study was conducted over six months at the University Children's Hospital in Damascus. A total of 575 children taking two drugs or more participated. pDDIs were checked using Lexi-Interact® software. pDDIs within risk category B (No action needed), C (Monitor therapy), D (Modify regimen), and X (Avoid combination) were included. Logistic regression was used to identify factors associated with pDDIs.\nResults: At least one pDDI was detected in 49.7% of children. Overall, 744 pDDIs were identified. The majority of pDDIs were within risk category C (71.6%), followed by D (14%), B (12.8%), and X (1.6%). The most common pDDIs were: aminoglycosides - penicillins (n=56), aminoglycosides - cephalosporins (n=27), and vitamin D analogs - calcium salts (n=23). The number of prescribed drugs and nervous system drugs were significantly associated with the presence of pDDIs.\nConclusion: pDDIs among pediatric inpatients were prevalent. The majority of the pDDIs were within risk category C, which necessitates therapy monitoring and necessary action to avoid adverse consequences.","PeriodicalId":14719,"journal":{"name":"Jordan Journal of Pharmaceutical Sciences","volume":"66 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jordan Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35516/jjps.v17i1.1606","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Polypharmacy among pediatric inpatients is common and exposes children to the risk of drug-drug interactions (DDIs). This study aimed to characterize potential DDIs (pDDIs) and their associated risk factors among pediatric inpatients.
Methods: A cross-sectional study was conducted over six months at the University Children's Hospital in Damascus. A total of 575 children taking two drugs or more participated. pDDIs were checked using Lexi-Interact® software. pDDIs within risk category B (No action needed), C (Monitor therapy), D (Modify regimen), and X (Avoid combination) were included. Logistic regression was used to identify factors associated with pDDIs.
Results: At least one pDDI was detected in 49.7% of children. Overall, 744 pDDIs were identified. The majority of pDDIs were within risk category C (71.6%), followed by D (14%), B (12.8%), and X (1.6%). The most common pDDIs were: aminoglycosides - penicillins (n=56), aminoglycosides - cephalosporins (n=27), and vitamin D analogs - calcium salts (n=23). The number of prescribed drugs and nervous system drugs were significantly associated with the presence of pDDIs.
Conclusion: pDDIs among pediatric inpatients were prevalent. The majority of the pDDIs were within risk category C, which necessitates therapy monitoring and necessary action to avoid adverse consequences.
期刊介绍:
The Jordan Journal of Pharmaceutical Sciences (JJPS) is a scientific, bi-annual, peer-reviewed publication that will focus on current topics of interest to the pharmaceutical community at large. Although the JJPS is intended to be of interest to pharmaceutical scientists, other healthy workers, and manufacturing processors will also find it most interesting and informative. Papers will cover basic pharmaceutical and applied research, scientific commentaries, as well as views, reviews. Topics on products will include manufacturing process, quality control, pharmaceutical engineering, pharmaceutical technology, and philosophies on all aspects of pharmaceutical sciences. The editorial advisory board would like to place an emphasis on new and innovative methods, technologies, and techniques for the pharmaceutical industry. The reader will find a broad range of important topics in this first issue.